Ansell share price surges 10% as full-year revenue comes in at US$1.9b

The healthcare giant's earnings have impressed experts.

| More on:
Three excited business people cheer around a laptop in the office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Ansell share price is taking off today, gaining 9.67% to trade at $27.57
  • It comes after the company released its earnings for financial year 2022 this morning
  • Experts have seemingly responded well to its results, with one reportedly recognising "solid underlying trends"

The Ansell Limited (ASX: ANN) share price is taking off following the release of the company's full-year earnings.

The S&P/ASX 200 Index (ASX: XJO) stock has continued on an upwards trajectory after opening 1.5% higher at $25.52.

At the time of writing, the Ansell share price is $27.57, 9.67% higher than its previous close.

Let's take a closer look at today's news from the personal protection and safety solutions provider.

Ansell share price rockets 10% on earnings

As The Motley Fool Australia reported earlier, Ansell posted US$1.95 billion of revenue and US$158.7 million of operating profit for financial year 2022.

Those figures mark respective year-on-year declines of 3.7% and 35.7%, mainly due to waning demand born from COVID-19.

Its earnings per share (EPS), meanwhile, came in within guidance at US$1.252 per share. That's bolstered to US$1.386 when adjusted for costs arising from the company's exit of Russia. Its decision to abandon operations in the nation brought a 13.4 US cent impact to its EPS.

Such a result has seemingly impressed the market. It's bid the Ansell share price to a multi-week high on the back of the company's announcement. The results also appear to have pricked the ears of experts.

Macquarie's David Bailey was quoted by The Australian as saying the company's financial year 2022 earnings embody "solid underlying trends".

The publication said the company's statutory result was in line with expectations, while its adjusted earnings were ahead. The expert continued, courtesy of The Oz:

For [financial year 2023], we see commentary ex-Russia and [foreign exchange] as highlighting improved trends and a basis for growth into [financial year 2024].

Ansell posted guidance of between US$1.15 and US$1.35 of EPS for financial year 2023.

Today's gains included, the Ansell share price is 16% lower than it was at the start of 2022. It has also fallen 31% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell Ltd. and Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »